Faecal calprotectin is a highly effective, non-invasive biomarker for distinguishing Inflammatory Bowel Disease (IBD) from Irritable Bowel Syndrome (IBS). With a sensitivity of 91.1% and a specificity of 86.7%, the study demonstrates that FC levels are significantly higher in IBD patients, making it a reliable and rapid diagnostic tool for clinical practice.

"The routine TDM of ADL can be performed with Promonitor and QB assays since trough levels and patient classification into therapeutic ranges are comparable. In the case of IFX trough levels, we must be cautious when using these new methods due to the differences found when classifying patients between the therapeutic and supra-therapeutic ranges. New ranges should probably be defined for using different methods and not be considered interchangeable, especially when monitoring patients’ maintenance therapies. On the other hand, QB appears to be a suitable method for the qualitative determination of ADAs and could be used individually or as an add-on to the measurement of levels via traditional methods. Nevertheless, further studies with larger sample sizes and comparing all currently available analytical methods in a simultaneous manner are needed to establish the interchangeability between them and, if necessary, new therapeutic ranges according to the analytical method used."

This study confirms that the QUANTUM BLUE sCAL rapid test (QBT) is an effective point-of-care tool for diagnosing peritonsillar abscess (PTA) in outpatient settings. By measuring calprotectin levels in serum and saliva, the QBT provides a faster alternative to traditional lab tests. When QBT results are combined with clinical symptoms to form an adjusted PTA score, the method achieves 100% sensitivity and 89.3% specificity. This allows for immediate, accurate diagnosis, helping clinicians avoid unnecessary surgery and reduce hospital stays.

"Our results clearly show that even the bedside test for fecal calprotectin level, using the optimal cut-off value, is feasible enough in determining candidates for an endoscopic procedure in order to confirm bowel inflammation and is more tightly associated with histological findings than with endoscopic findings. Thus, the calprotectin level reflects histological activity, even in cases with normal endoscopic findings. The bedside test described herein is a sufficient screening method for this purpose."

"Ascitic calprotectin reliably predicts PMN count > 250/μL, which may prove useful in the diagnosis of SBP, especially with a readily available bedside testing device."

"Fecal calprotectin concentration has good diagnostic accuracy for the detection of endoscopic activity in inflammatory bowel disease and performs better in ulcerative colitis than in Crohn's disease."

"The results of the two rapid FC assays iChroma and Buhlmann showed a significant correlation, but the two test results were not interchangeable. With optimized cut-off values, rapid FC tests could be helpful in the diagnosis of IBD and differentiating active IBD from inactive or organic bowel disease."

"Measurements of fecal levels of calprotectin made with home-based lateral flow method were in agreement with measurements made by Quantum Blue and ELISA, as long as concentrations were <500 μg/g. For patients with concentrations of fecal calprotectin above this level, findings from IBDoc should be confirmed by another method. (Netherlands Trial Registration Number: NTR5133)."

"The Thermo Fisher device is not reliable for extraction of faecal calprotectin. The performance characteristics of the EliA Calprotectin assay are statistically equivalent to the Bühlmann POCT."

"Due to good performance characteristics and agreement with established methods, the fully automated PETIA on the routine chemistry analyzer VITROS® 5600 is a new analytical option for the rapid determination of FC."

"We may conclude that the point-of-care test can serve as a reliable alternative to the time consuming ELISA in the differential diagnosis between functional and organic bowel disease. Furthermore, it seems to be reliable in the follow-up of inflammatory bowel disease patients."

"Our results confirm the effective use of fecal calprotectin levels in differentiating non-inflammatory from active inflammatory intestinal diseases. The desk top Bühlmann Quantum Blue Reader® exhibits a fast, non-invasive, and reliable way of identifying an inflammatory intestinal disease."

"Although all three methods correlated well and had relatively good NPV in terms of detecting relapses amongst a Crohn's population in follow-up, the lack of any international standard is the origin of different optimal cut-offs between the three procedures."

"The fCAL turbo assay performs well on the Binding Site, Optilite benchtop analyser. Calprotectin results are commutable between with Bühlmann fCAL turbo and Quantum Blue fCAL extended assays, but not between Bühlmann and DiaSorin calprotectin assays."